NasdaqCM - Delayed Quote USD

Medicus Pharma Ltd. (MDCX)

2.5500
-1.0850
(-29.85%)
At close: May 30 at 4:00:02 PM EDT
2.5300
-0.02
(-0.78%)
After hours: May 30 at 7:32:56 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MDCX

Recent News: MDCX

View More
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari

Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
GlobeNewswire yesterday
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
Newsfile 2 days ago
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Newsfile 9 days ago
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Newsfile last month
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Newsfile last month
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
Newsfile 2 months ago
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering

Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
Newsfile 2 months ago
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Newsfile 2 months ago
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
GlobeNewswire 3 months ago
Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
Newsfile 3 months ago
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
GlobeNewswire 5 months ago
View More

Related Tickers

SCLX Scilex Holding Company
5.12
-9.38%
 
SNY Sanofi
49.37
-5.69%
 
AZN AstraZeneca PLC
72.83
+2.77%
 
AMRN Amarin Corporation plc
11.59
-0.77%
 
AMGN Amgen Inc.
288.18
+1.64%
 
OGN Organon & Co.
9.22
-3.35%
 
NVS Novartis AG
115.76
+2.82%
 
NONOF Novo Nordisk A/S
70.98
+2.57%
 
MRK Merck & Co., Inc.
76.84
+0.58%
 
BMY Bristol-Myers Squibb Company
48.28
+0.90%